Enlivex Therapeutics Faces Financial Challenges Amid Losses

Enlivex (ENLV) has released an update.

Enlivex Therapeutics Ltd. reported a significant net loss of $9.8 million for the nine months ending September 30, 2024, compared to $19.97 million the previous year. The company’s assets decreased to $29.8 million from $36.8 million at the end of 2023, with a decline in both current and non-current assets. This financial performance reflects ongoing challenges in managing operating expenses, particularly in research and development.

For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.